ArticlePrecision radiation oncology2025
Evaluating the trade-off between plan complexity, dosimetric accuracy, and treatment efficiency: Role of aperture shape controller settings in HyperArc for intracranial oligometastases.
Article in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the impact of different aperture shape controller (ASC) stratification strategies on the dosimetric quality and treatment efficiency of HyperArc plans for intracranial oligometastases. Methods: This retrospective study analyzed 17 patients with 1-3 intracranial oligometastases. For each patient, the HyperArc plans were reoptimized using six ASC strength settings (off, very low, low, moderate, high, and very high). Evaluations encompassed planning target volume (PTV) and organ at risk (OAR) dosimetric parameters (Paddick Conformity Index [Paddick CI], Gradient Index [GI], D Results: No statistically significant differences were observed in the PTV and OAR dosimetric parameters or gamma passing rates among the ASC strategy groups ( Conclusions: ASC stratification strategies do not significantly compromise plan dosimetric quality in HyperArc treatment for intracranial oligometastases; however, these can markedly optimize treatment efficiency, particularly by reducing MUs. Considering both plan complexity and treatment efficiency, a moderate or high ASC strength is recommended to maintain high-quality radiotherapy while improving workflow efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.